- Court Filing

- SEC Filing

Upgrades According to B of A Securities, the prior rating for Futu Holdings Ltd (NASDAQ:FUTU) was changed from Underperform to Buy. In the second quarter, Futu Hldgs showed an EPS of $1.09, compared to $0.61 from the year-ago quarter. The stock has a 52-week-high of $72.20 and a 52-week-low of $28.01. At the end of the last trading period, Futu Hldgs closed at $51.06. According to Truist Securities, the prior rating for Apartment Income REIT Corp (NYSE:AIRC) was changed from Hold to Buy. In the second quarter, Apartment Income REIT showed an EPS of $0.58, compared to $0.66 from the year-ago quarter. At the moment, the stock has a 52-week-high of $43.70 and a 52-week-low of $32.51. Apartme

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Timber Pharmaceuticals (AMEX:TMBR) from Buy to Neutral.

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 1.5% on Monday. The Dow traded down 0.16% to 34,446.91 while the NASDAQ rose 1.52% to 13,492.73. The S&P 500, also rose, gaining, 0.55% to 4,393.55. Check This Out: This Analyst With 86% Accuracy Rate Sees Over 15% Upside In NVIDIA - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts  Leading and Lagging Sectors Information technology shares rose by 2% on Monday. In trading on Monday, real estate shares fell by 1%.  Top Headline Palo Alto Networks, Inc. (NYSE:PANW) reported better-than-expected fourth-quarter earnings and issued strong billings outlook for the year

Gainers China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) shares jumped 120% to $0.33. Timber Pharmaceuticals, Inc. (NYSE:TMBR) gained 97.1% to $2.7993 as the company agreed to be acquired by LEO US Holding, Inc., a wholly-owned subsidiary of LEO Pharma A/S, for a total transaction value of $36 million.. MediaCo Holding Inc. (NASDAQ:MDIA) jumped 38.5% to $0.79. Novo Integrated Sciences, Inc. (NASDAQ:NVOS) gained 39% to $0.1849. Tian Ruixiang Holdings Ltd (NASDAQ:TIRX) shares surged 34.2% to $1.45. Fresh Vine Wine, Inc. (NYSE:VINE) gained 32% to $0.41. China Pharma Holdings, Inc. (NYSE:CPHI) climbed 26.5% to $0.2771. STRATA Skin Sciences, Inc. (NASDAQ:SSKN) surged 24.1% to $0.7829. Gen

LAVAL, Quebec, March 25, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST) today announces that it has appointed Michael L. Derby to its Board of Directors. "Michael is a successful pharma industry leader whose extensive involvement in drug repurposing and his passion for developing and commercializing innovative products that positively impact patients' lives will prove to be invaluable as we advance our three lead clinical assets," stated Dr. Roddy Carter, Chairman of the Board of Acasti. "We anticipate benefitting from his perspective and broad experience." Mr. Derby brings more than two decades of experience and a proven track record wit

- Edward J. Sitar appointed as Lead Independent Director of the Board - - Company establishes Science and Technology Committee to be chaired by Dr. David Cohen - Basking Ridge, NJ, April 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that Chief Executive Officer John Koconis has been appointed as Chairman of the Board of Directors. The Company also announced that Edward J. Sitar has been appointed as Lead Independent Director of the Board and David Cohen, M.D., will

Dr. Mendelsohn has 20+ Years’ Experience in Clinical Development and Medical Affairs WOODCLIFF LAKE, NJ, Jan. 25, 2021 (GLOBE NEWSWIRE) --   via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced the appointment of Alan Mendelsohn, M.D., as Chief Medical Officer. Dr. Mendelsohn assumes the roles and responsibilities of Amir Tavakkol, Ph.D., who will be stepping down as the Company’s Chief Scientific Officer.  “We are pleased to welcome Dr. Mendelsohn to our management team. Dr. Mendelsohn

8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)

8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)

8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)

25-NSE - Timber Pharmaceuticals, Inc. (0001504167) (Subject)

8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)

8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)

8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)

NT 10-Q - Timber Pharmaceuticals, Inc. (0001504167) (Filer)

DEFA14A - Timber Pharmaceuticals, Inc. (0001504167) (Filer)

425 - Timber Pharmaceuticals, Inc. (0001504167) (Subject)

SC 13G - Timber Pharmaceuticals, Inc. (0001504167) (Subject)

SC 13G/A - Timber Pharmaceuticals, Inc. (0001504167) (Subject)

SC 13G/A - Timber Pharmaceuticals, Inc. (0001504167) (Subject)

SC 13G/A - Timber Pharmaceuticals, Inc. (0001504167) (Subject)

SC 13D/A - Timber Pharmaceuticals, Inc. (0001504167) (Subject)

SC 13D/A - Timber Pharmaceuticals, Inc. (0001504167) (Subject)

SC 13D/A - Timber Pharmaceuticals, Inc. (0001504167) (Subject)

SC 13G/A - Timber Pharmaceuticals, Inc. (0001504167) (Subject)

4 - Timber Pharmaceuticals, Inc. (0001504167) (Issuer)

4 - Timber Pharmaceuticals, Inc. (0001504167) (Issuer)

4 - Timber Pharmaceuticals, Inc. (0001504167) (Issuer)

4 - Timber Pharmaceuticals, Inc. (0001504167) (Issuer)

4 - Timber Pharmaceuticals, Inc. (0001504167) (Issuer)

4 - Timber Pharmaceuticals, Inc. (0001504167) (Issuer)

4 - Timber Pharmaceuticals, Inc. (0001504167) (Issuer)

4 - Timber Pharmaceuticals, Inc. (0001504167) (Issuer)

4 - Timber Pharmaceuticals, Inc. (0001504167) (Issuer)

4 - Timber Pharmaceuticals, Inc. (0001504167) (Issuer)

WARREN, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the staff of NYSE Regulation (the "NYSE Regulation") has determined to immediately suspend trading in the Company's common stock from NYSE American, LLC (the "NYSE American"). As previously disclosed, the NYSE Regulation notified Timber on November 21, 2023 that, as a result of the voluntary bankruptcy petitions filed under Chapter 11 of the United States Bankruptcy Code by the Company and certain of its

WARREN, NJ, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, and its affiliated debtors and debtor-in-possession ("Timber" or the "Company"), today announced that all "first day" motions related to the Company's voluntary Chapter 11 petitions for reorganization filed on November 17, 2023, were approved on an interim basis by the U.S. Bankruptcy Court for the District of Delaware. At the hearing, among other things, the Court approved an initial $3.0 million in interim funding pursuant to a debt

WARREN, NJ, Sept. 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the NYSE American LLC (the "NYSE American") has accepted the Company's business plan to regain compliance with the continued listing standards set forth in Sections 1003(a)(i) and (ii) of the NYSE American Company Guide. As previously disclosed, on June 28, 2023, the Company received written notice from the NYSE American that the Company was not in compliance with Sections 1003(a)(i)

NEW YORK, Aug. 26, 2023 (GLOBE NEWSWIRE) -- Timber Pharmaceuticals, Inc. (NYSE:TMBR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of TMBR to LEO Pharma A/S for (i) an initial upfront consideration of $14 million and (ii) up to an additional $22 million in contingent value rights payable upon achievement of specific milestones for TMB-001. If you are a TIMBR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Permian Resources Corporation (NYSE:PR)

Transaction Provides Timber Stockholders with Upfront Cash Consideration and Downstream Value through Contingent Value RightsTotal Transaction Value of up to $36 millionTransaction Expected to Close in the 4th Quarter of 2023, subject to closing conditions and stockholder approval WARREN, NJ, Aug. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR) today announced that it has entered into a definitive agreement to be acquired by LEO US Holding, Inc. ("LEO Pharma"), a wholly-owned subsidiary of LEO Pharma A/S, in a total transaction value of up to $36 million with (i) an initial upfront consideration of $14 million and (ii

WARREN, NJ, July 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that on June 28, 2023 it received a letter (the "Notice") from the NYSE American LLC ("NYSE American" or the "Exchange") advising the Company is not in compliance with the NYSE American continued listing standards set forth in Sections 1003(a)(i) and (ii) of the NYSE American Company Guide given the reported stockholders' deficit as of March 31, 2023, and losses from continuing operations and/or

- First Presentation of Data From Phase 3 ASCEND Study Will Feature Pharmacokinetic Results That Indicate Minimal Systemic Absorption of Isotretinoin - - Data to be Presented at the Society for Pediatric Dermatology's Annual Meeting - WARREN, NJ, June 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that interim pharmacokinetic (PK) analyses from the Phase 3 ASCEND study indicate minimal systemic absorption of isotretinoin or its major metabolites in pat

- Phase 3 ASCEND study of TMB-001 (topical isotretinoin) for the treatment of congenital ichthyosis is 70% enrolled - WARREN, NJ, June 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced the U.S. Food and Drug Administration (FDA) has granted a dermal carcinogenicity (CARC) waiver for TMB-001, a topical isotretinoin formulated using the Company's patented IPEG™ delivery system. The positive opinion is based on results of a 39-week repeat dose dermal toxicity st

- Timber has now Enrolled Over 60% of Patients for Pivotal TMB-001 Phase 3 ASCEND Clinical Trial - WARREN, NJ, May 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023. John Koconis, Chairman and Chief Executive Officer of Timber, commented, "The development of our lead asset, TMB-001, continued to progress on several fronts during the first quarter of 2023. In February 2

- Lead asset TMB-001 is only compound to receive official orphan drug designation from European Commission for two severe subtypes of congenital ichthyosis, ARCI and XLRI - - Timber has enrolled 50% of patients for pivotal TMB-001 Phase 3 ASCEND clinical trial - WARREN, NJ, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the fourth quarter and year ended December 31, 2022. John Koconi